Pharma BD Deal Intelligence

Novartis AG / Gyroscope Therapeutics

2021 · Acquisition/Merger · $1.5B · Complete

A $1.5B all-cash acquisition that gave Novartis a clinical-stage gene therapy for retinal disease, but the deal has since scored as a bust—Gyroscope's pipeline failed to deliver the outcomes Novartis was betting on.

WRONG BY 65 POINTS
Full analysis, sources & comparables →

The coverage arc

Dec 18, 2002 Wikipedia Neutral

Novartis acquired Gyroscope Therapeutics for $1.5B for gene therapy for retinal diseases.

Dec 23, 2021 Pharmaceutical Technology Bullish

Novartis to acquire Gyroscope Therapeutics for up to $1.5 billion for gene therapy targeting geographic atrophy.

Source summaries from our enrichment pipeline; follow links for originals.

All 4 sources with sentiment breakdown →

Novartis acquired Gyroscope Therapeutics for $1.5B for gene therapy for retinal diseases.

Key facts

Disease & market context

Geographic Atrophy (Retinal Gene Therapy)

200K US cases/yr · $1.2B Global GA Market (2024)

Disease Overview

GA is advanced dry AMD causing irreversible vision loss in ~5M globally. Complement inhibitors first approved treatments. Gene therapy aims for sustained delivery.

Competitive Landscape

Apellis (Syfovre), Astellas (Izervay) approved. Novartis/Gyroscope gene therapy (GT005, CFI delivery) aims for one-time vs monthly injections.

Deal timeline

Related deals — scored

DealYearValueOutcome
Novartis AG / Gyroscope Therapeutics (this deal)2021$1.5B23
Novartis AG / Advanced Accelerator Applications S.A.2017$3.9B98
Novartis AG / Endocyte, Inc.2018$2.1B96
Novartis AG / Lek Pharmaceuticals d.d.2002$876M88
Novartis AG / GlaxoSmithKline plc2014$16.0B81
Novartis AG / PTC Therapeutics Inc.2024$2.9B80
Novartis AG / Chinook Therapeutics Inc.2023$3.5B78

Compare all 7 side-by-side →

See the full interactive analysis, sources & comparables →